Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravitreal Conbercept vs Lucentis for Macular Edema Secondary to BRVO
ChiCTR-IPR-16009191Phase 4Recruiting
- Sponsor
- Shandong Provincial Hospital Affiliated to Shandong First Medical University
- Start
- Sep 2016
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised trial of conbercept in branch retinal vein occlusion (BRVO) (2 arms), sponsored by Shandong Provincial Hospital Affiliated to Shandong First Medical University. Primary endpoint: VISUAL ACUITY. Started Sep 2016; status: recruiting.
02
Drugs
conbercept
03
Conditions
branch retinal vein occlusion (BRVO)
Beyond the preview
Go deeper on ChiCTR-IPR-16009191.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-16009191.